- Aeterna Zentaris (AEZS) has updated results from pre-clinical studies of its AIM Biologicals platform to treat Parkinson’s disease
- AIM Biologicals showed a trend towards improved motoric function
- It also showed stimulation of regulatory cells and recovery of functional neurons
- The data presented showed consistent results in various in-vitro and in-vivo models
- Aeterna Zentaris Inc. (AEZS) is down 4.69 per cent trading at $0.30 pr share as of 4:34 p.m. ET
Aeterna Zentaris (AEZS) has updated results from pre-clinical studies of its AIM Biologicals platform to treat Parkinson’s disease.
The company reported that its AIM Biologicals showed a trend towards improved motoric function, stimulation of regulatory cells, and recovery of neurons responsible for regulating movement and coordination.
The company utilized an animal model on neurodegeneration by inhibiting neurotransmitter released cells in mice with Parkinson’s disease and explored whether novel tolerance-inducing biomolecules can inhibit neurodegeneration and prevent Parkinson’s in-vivo.
The pre-clinical data presented showed consistent results in various in-vitro and in-Vivo models, verifying the potential of molecules being able to induce antigen-specific immune modulation.
Treatment with these molecules (AIM Biologicals) leads to sequenced cell death of antigen-specific toxic cells, and to the stimulation of regulatory cells.
AIM Biologicals are specialty autoimmunity modifying therapeutics. The scientific concept behind the platform technology is a precondition of successful pregnancy in mammals.
During pregnancy, the immune system of mothers does not attack the fetus, which consists of 50 per cent paternal proteins. For this, the immune system is not downregulated, but selectively de-sensitized ensuring that the mothers continue to be protected against infections.
Aeterna Zentaris Inc. (AEZS) is down 4.69 per cent trading at $0.30 pr share as of 4:34 p.m. ET.